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ABSTRACT
Cigarette smoking is associated with increased risk for all histologic types of 
lung cancer, but why the strength of this association is stronger for squamous cell 
carcinoma than adenocarcinoma of the lung (SQC-L, ADC-L) is not fully understood. 
Because nicotine and tobacco-specific nitrosamines contribute to carcinogenesis by 
activating nicotinic acetylcholine receptors (nAChRs) on lung tumors and epithelial 
cells, we investigated whether differential expression of nAChR subtypes in these 
tumors could explain their different association with smoking. Expression of nAChR 
subunit genes in paired tumor and non-tumor lung specimens from 40 SQC-L and 38 
ADC-L patients was analyzed by quantitative PCR. Compared to normal lung, both 
tumors share: i) transcriptional dysregulation of CHRNA3/CHRNA5/CHRNB4 (α3, 
α5, β4 subunits) at the chromosomal locus that predisposes to lung cancer; and ii) 
decreased expression of CHRFAM7A (dupα7 subunit); this last subunit negatively 
modulates α7-nAChR activity in oocytes. In contrast, CHRNA7 (α7 subunit) expression 
was increased in SQC-L, particularly in smokers and non-survivors, while CHRNA4 
(α4 subunit) expression was decreased in ADC-L. Thus, over-representation of 
cancer-stimulating α7-nAChR in SQC-L, also potentiated by smoking, and under-
representation of cancer-inhibiting α4β2-nAChR in ADC-L could explain the different 
tobacco influences on the tumorigenic process in each cancer type.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
deaths worldwide [1]. There are two major categories 
of lung cancer, non-small cell lung carcinoma (NSCLC) 
and small-cell lung carcinoma (SCLC), respectively 
accounting for 75–85% and 15–25% of all lung cancer 
cases. Lung adenocarcinoma (ADC-L) and squamous 
cell carcinoma of the lung (SQC-L) are the two major 
histologic types of NSCLC, which also includes large-cell 
lung carcinoma (LCLC) as a minor type.
Numerous epidemiologic and laboratory-based 
studies have confirmed that cigarette smoking is 
associated with increased risk for all major histological 
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types of lung cancer, which is understandable given that 
tobacco contains more than 70 known carcinogens [2]. 
However, it is surprising how much the strength of the 
above association varies between the different histological 
tumor types, being stronger with SCLC and SQC-L than 
LCLC and ADC-L [3]. One of the hypotheses to justify 
the variation in the risk associated with smoking for one 
or the other tumor type, is related to the location and more-
or-less intimate exposure of the tumor to inhaled tobacco 
smoke and its carcinogenic components. This hypothesis 
would explain why the more peripheral tumors (ADC-L 
and LCLC) show weaker associations with smoking 
than the more central tumors (SQC-L or SCLC) [4]. 
However, the above proposal does not exclude a second, 
so far never-explored possibility that would imply tumor-
dependent differential expression of target receptors for 
the carcinogenic components of tobacco. 
Tobacco smoke contains multiple classes 
of carcinogens, including polycyclic aromatic 
hydrocarbons and the nicotine-derived nitrosamines 
4-(methylnitrosamino)-1-(3-pyrydyl)-1-butanone (NNK) 
and N-nitrosonornicotine (NNN). By inducing the 
formation of DNA adducts and causing mutations in vital 
cancer suppressor genes (i.e. Rb, p53 and K-Ras), these 
carcinogens eventually initiate carcinogenesis [5]. At the 
same time, the addictive components of tobacco, nicotine 
and its carcinogenic derivatives NNK and NNN, also 
significantly contribute to the oncogenic process after 
binding and activating cell surface nicotinic acetylcholine 
receptors (nAChRs) expressed in neuronal and non-
neuronal cells, including the cancer cells themselves 
[6]. Stimulating the receptors in the cancer cells leads to 
downstream activation of multiple signaling cascades that 
promote cancer cell survival, proliferation, angiogenesis, 
migration and metastasis in a tumor-specific manner 
[7–10]. The nAChRs are complex structures composed 
of five transmembrane subunits arranged around a central 
ion pore [11]. To date, several alpha (α3-α7, α9) and beta 
(β2 and β4) nAChR subunits have been identified in 
primary lung tumors and human lung cancer cell lines [see 
Ref. 12 and references therein]. Accordingly, it is likely 
that the above tumors express homomeric α7- and α9-
nAChRs (composed of five identical α7 or α9 subunits) 
and heteromeric α3β4α5-, α3β2α5- and α4β2-nAChRs 
(constituted by different combinations of α and β subunits). 
The different subunit compositions of nAChR 
determine its functional and pharmacological 
characteristics as well as its pathophysiological role. In 
relation to this last aspect, α9-nAChRs are known to play 
an important role in human breast cancer progression [13], 
while α7-nAChR is the main subtype responsible for the 
nicotine-mediated proliferative, pro-angiogenic and pro-
metastatic effects in human NSCLC [14–17]. In contrast 
to the α7-nAChR-mediated stimulatory effects on cancer 
growth, heteromeric α4β2-nAChR seems to be one of the 
major inhibitors of cancer development and progression 
through its release of GABA, which blocks the cancer-
stimulating effects of β-adrenergic receptors by inhibiting 
cAMP [18]. It is interesting to note that chronic exposure 
to nicotine, and its carcinogenic derivative NNK, increases 
cancer-stimulating α7-nAChR expression and desensitizes 
cancer-inhibiting α4β2-nAChR in cancer cells in the 
lungs and pancreas [16, 19, 20]. This means that smoking 
activates cancer-stimulating nAChRs in the cells.
Genes CHRNA3, CHRNA4, CHRNA5, CHRNA6, 
CHRNA7, CHRNA9, CHRNB2 and CHRNB4, located 
across different chromosomes, respectively encode for 
the α3, α4, α5, α6, α7, α9, β2 and β4 nAChR subunits 
expressed in lung cancer cells [see Ref. 12 and references 
therein]. Several genome-wide association studies 
(GWAS) have identified a susceptibility locus for 
human lung cancer at chromosome 15q24-25, which 
contains three of the above genes: CHRNA3/CHRNA5/
CHRNB4 [21–23]. The discovery of a new hybrid gene 
(CHRFAM7A) in the human genome, but not in that of 
other higher primates, is also noteworthy. The hybrid 
gene results from the fusion of a partial duplication of the 
CHRNA7 gene with the FAM7A gene [24, 25]. Moreover, 
the CHRFAM7A transcript, named dupα7 mRNA, has been 
identified in brain (hippocampus, cortex, corpus callosum, 
thalamus, putamen, caudate nucleus and cerebellum) 
and in the periphery (peripheral blood mononuclear 
cells, lymphocytes and synoviocytes) [see Ref. 26 and 
references therein]. Moreover, our group performed the 
first study on the functional role of the new dupα7-nAChR 
subunit heterologous expressed in Xenopus oocytes, 
demonstrating that it behaves as a negative endogenous 
regulator of α7-nAChR activity [26]. Given the prominent 
role of α7-nAChR in the development of lung cancer, it is 
feasible that dupα7 could act as an endogenous suppressor 
of tumor growth mediated by α7-nAChRs, as long as this 
atypical subunit was expressed in the tumor. To date, there 
have been no data in the literature on this question.
The present study aims to determine whether 
differences in the expression pattern for the genes 
encoding nAChR subunits that make up target receptors 
for the carcinogenic components of tobacco could explain 
the variability of the influence of tobacco in the two major 
histologic types of NSCLC. To address this issue, we have 
used real-time quantitative polymerase chain reaction 
(qPCR) to examine normalized or absolute mRNA 
expression levels of several nAChR subunits in lung 
biopsies from 40 patients with SQC-L and 38 patients with 
ADC-L. Each patient provided matched specimens, one of 
non-tumor lung tissue and another from their lung tumor.
RESULTS
Demographic and clinical characteristics of 
patients
Seventy-eight NSCLC patients were included in the 
study and their demographic and clinical characteristics 
are summarized in Table 1. Patients were grouped 
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according to their histologic tumor type [40 SQC-L 
(51.3%) and 38 ADC-L (48.7%)], gender (with a majority 
of men in both tumor types) and age (87% of SQC-L and 
92.1% of ADC-L patients were over 60 years old). Most 
SQC-L patients were smokers (87.5%) at the time of 
diagnosis with a history of tobacco consumption averaging 
at least 20 packs per year, while more than half of the 
ADC-L patients (55.3%) were non-smokers or second-
hand smokers. The tumor differentiation grade according 
to the 2015 WHO classification of lung cancer [27] and 
long-term outcomes are also summarized in Table 1. 
Expression of nAChR subunit gene in tumor 
biopsies of SQC-L and ADC-L patients 
Gene expression of nAChR subunits was analyzed 
in matched tumor and non-tumor lung specimens from 
each patient included in the study. The upper panels of 
Figure 1A and 1B show the gene expression for each 
subunit in the tumor sample normalized with respect to 
its non-tumor partner for both groups of patients. The 
results for SQC-L tumors showed a significant increase in 
α5, α7 and β4, together with a significant decrease in α3, 
dupα7 and β2 mRNA levels (Figure 1A). We also found 
that ADC-L and SQC-L tumors shared significant changes 
in the expression of some nAChR genes (increased α5 and 
β4 and reduced α3 and dupα7 mRNA levels). However, 
differently from the latter, ADC-L tumors showed a 
significant reduction in α4 mRNA level without significant 
changes in the expression of α7 or β2 mRNAs (Figure 1B).
Our data concerning the normalized α7 and 
dupα7 mRNA expression in tumors of SQC-L and 
ADC-L patients were subsequently corroborated by the 
absolute expression values (number of mRNA copies) 
of both messengers determined in paired tumor and 
non-tumor biopsies from the patients (Figure 1C). The 
results revealed that, compared to non-tumor specimens, 
only SQC-L tumors showed a significant increase in 
absolute α7 mRNA expression, but that both tumor types 
shared a significant reduction in the number of dupα7 
mRNA copies. Using the absolute expression values 
of both messengers in the SQC-L and ADC-L tumors, 
we calculated the quotient of α7 versus dupα7 mRNA 
molecules in each histological type as a α7/dupα7 ratio. 
The results demonstrate that, in comparison to ADC-L, 
SQC-L tumors contain a significantly higher proportion 
of α7 than dupα7 mRNA molecules (Figure 1D).
Frequency distribution and correlation analysis 
of α7 expression versus expression of each of 
the remaining nAChR subunits in SQC-L and 
ADC-L tumors
To obtain complementary information for that 
provided by Figure 1 in the groups of SQC-L and ADC-L 
patients, we next analyzed the frequency distribution 
for two categorical variables (α7 versus another nAChR 
subunit), each with two categories (higher or lower mRNA 
expression in the tumor compared to its paired non-tumor 
sample) in each group. The α7 subunit was chosen as the 
fixed variable for comparison against each of the remaining 
variables (another nAChR subunit) because the α7-nAChR 
subtype is the most directly involved in tobacco-induced 
tumorigenesis. With the qualitative data from above, we 
produced a contingency table for each tumor type that 
was later transformed into the corresponding “stacked bar 
chart” (Figure 2) to facilitate visual comparison between 
categories (see the insert with the colored categories to the 
right of the figure). The numbers inside the stacked bars 
correspond to the percentage of patients in each segment. 
The results in SQC-L patients show a statistically 
significant relationship between α7 mRNA expression and 
expression of dupα7, α3, α5, β2 or β4 mRNA (panel A). 
In addition, we found that the most frequent distribution 
in these patients was the one with increased expression of 
α7 mRNA in their tumors, which was accompanied by a 
decreased expression of dupα7 (43% of the patients, purple), 
α3 (44%, purple), β2 (44%, purple), or increased expression 
of α5 (54%, orange) and β4 (70%, orange). It should be 
noted that tumor levels of dupα7, α3 and β2 mRNAs are 
decreased and those of α5 and β4 increased in most SQC-L 
patients (73%, 75%, 75%, 64% and 89%, respectively).
Figure 2B shows that for patients with ADC-L, the 
frequency distribution for each pair of variables differs 
from that found in SQC-L patients. Therefore, the most 
common distribution in ADC-L patients corresponds to 
that with diminished expression of α7 and the remaining 
related variables [dupα7 (41%), α3 (42%), α9 (38%) and 
β2 (42%) = green], in their tumors. It is also noteworthy 
that, regardless of their α7 expression, most ADC-L 
patients showed reduced tumor expression of dupα7, 
α3, α9 and β2 (70%, 68%, 62% and 74%, respectively). 
The statistical analysis of our data does not detect an 
association between α7 and α4 expression in ADC-L 
tumors. However, and curiously, most ADC-L patients 
(84%) present a down-regulation of α4 subunit gene 
expression that is accompanied by either up-regulation (in 
44%) or down-regulation (in 40%) of α7 expression. 
Our results also reveal the significant correlation 
between α7 mRNA expression levels and the level of 
expression of other nAChR subunits (dupα7, α3 and β2) 
in both tumor subtypes (Table 2). Moreover, α7 expression 
levels also correlate with those of α5 mRNA in SQC-L, 
and with those of α4, α9 and β4 mRNAs in ADC-L tumors.
Association of smoking, tumor differentiation 
grade, and gender with the expression levels of 
several nAChR subunit genes in tumor biopsies 
from SQC-L and ADC-L patients
SQC-L is the type of NSCLC most strongly 
associated with cigarette smoking, while ADC-L, as 
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well as being the most common lung cancer in “never-
smokers”, is the one that shows the weakest association. 
Thus, we investigated whether tobacco exposure 
modified the expression profile of the nAChR subunit 
mRNAs in the tumors differently, depending on their 
histologic type. Figure 3A shows only those mRNAs 
whose normalized expression in SQC-L tumors appears 
to have been significantly affected by tobacco. Note the 
higher expression of all the affected nAChR subunits 
(α7, dupα7, α5 and α9) in smokers compared to non-
smokers, indicating that tobacco components up-regulate 
the expression of a few nAChR subunit genes in this 
histologic type. In contrast, none of the nAChR subunit 
mRNAs tested in patients with ADC-L showed changes in 
their expression level that could be associated to tobacco 
use (data not shown).
We also explored whether the degree of tumor 
differentiation in either histologic type could be associated 
to changes in the expression patterns of the nAChR 
subunit mRNAs. Figure 3B shows that only two subunits 
(α7 and α5) showed significantly increased expression in 
SQC-L tumors with a poor prognosis. However, the degree 
of tumor differentiation did not alter the gene expression 
of any of the nAChR subunits assayed in ADC-L patients 
(data not shown). No significant gender-related expression 
differences were found for any of the nAChR subunit 
genes tested in either of the two tumor types.
Gene expression pattern of different nAChR 
subunits in tumors of NSCLC patients and their 
relationship with survival 
Next, we investigated possible differences in the 
expression pattern of nAChR subunit mRNAs between 
patients with SQC-L or ADC-L who survived or died within 
5 years after surgery. Among all the subunits analyzed, 
Table 1: Demographic and clinical characteristics of NSCLC patients 
Histologic type SQC-La ADC-La 
Number of tumor biopsies 40 (51.3%) 38 (48.7%)
Gender
 Male
 Female
32 (80%)
8 (20%)
25 (65.8%)
13 (34.2%)
Age
 < 60
 > 60
5 (12.5%)
35 (87.5%)
3 (7.9%)
35 (92.1%)
Tobacco habit 
 Never smoker
 Second-hand smoker 
 Smoker
3 (7.5%)
2 (5.0%)
35 (87.5%)
11 (29.0%)
10 (26.3%)
17 (44.7%)
Differentiation grade
 Well/Moderate 
 Poor 
22 (55%)
18 (45%)
18 (47.4%)
20 (52.6%)
Clinical outcome
 Disease-free survival (median)
 Five-year survival rate (%)
47 months
60.0
54 months
68.4
aA non-tumor lung biopsy resected from each patient is analyzed in parallel to the paired tumor biopsy.
Table 2: Correlation between expression levels of α7 and other nAChR subunits in tumors from 
NSCLC patients
dupα7 α3 α4 α5 α9 β2 β4
SQC-L → α7 
ADC-L → α7 
0.395
(p = 0.012)
0.548
(p = 0.001)
0.537
(p = 0.0001)
0.676
(p = 0.0001)
−0.221
(ns)
0.475
(p = 0.008)
0.506
(p = 0.001)
0.246
(ns)
0.302
(ns)
0.636
(p = 0.0001)
0.438
(p = 0.005)
0.685
(p = 0.0001)
0.281
(ns)
0.387
(p = 0.031)
Values represent the Spearman correlation coefficients. The statistical significance is shown in parentheses, ns = not 
significant.
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only α7 mRNA levels in SQC-L tumors showed significant 
differences between survivors and non-survivors. Thus, 
SQC-L patients who died presented significantly higher 
tumor α7 mRNA levels than those who survived. In 
contrast, none of the nAChR subunit mRNAs, including 
α7, showed any difference in expression level between 
ADC-L survivors and non-survivors (Figure 4, right).
DISCUSSION
This study reveals, for the first time, the existence 
of differences and similarities in the expression pattern 
of nAChR subunit genes between lung tumor biopsies 
from patients with SQC-L or ADC-L. Compared with 
their paired non-tumorous lung specimens, the most 
Figure 1: Expression analysis of different nAChR subunit genes in lung tumor biopsies from NSCLC patients. 
Expression of each gene was determined by quantitative PCR in 40 patients with SCQ-L (A) and 38 patients with ADC-L (B). Each value, 
obtained in triplicate and representing an average of three separate determinations, was normalized with respect to the expression of the 
same gene in the corresponding paired non-tumoral (NT) sample from the same patient (referred to as 1). Data are represented as a box-and-
whisker plot; the line within each box shows the median expression of each subunit, upper and lower edges of the box represent the 75th 
and 25th percentile, and the ends of the whiskers the 90th and 10th percentile, respectively. The Wilcoxon test for paired samples was used 
for data analysis. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to the paired non-tumor sample. (C) Dot plots representing the absolute 
expression number of mRNA copies for the α7 and dupα7 expressed in paired non-tumor (NT) and tumor (T) lung biopsies of 40 patients 
with SQC-L and 33 patients with ADC-L; panels show the median and interquartile ranges for each gene analyzed. (D) The α7/dupα7 ratio 
was calculated on the basis of the number of copies of both transcripts expressed in the tumor biopsies of the patients. Wilcoxon (C) and 
Mann-Whitney (D) tests were used for data analysis. *p < 0.05; **p < 0.01; ***p < 0.001, ns = not significant. 
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substantial differences are the up-regulation of CHRNA7 
expression in SQC-L, particularly in smokers and non-
survivors, and the down-regulation of CHRNA4 in 
ADC-L. Our study also provides novel data on negative 
regulation of CHRFAM7A expression in SQC-L and 
ADC-L tumors; this gene encodes the new dupα7 nAChR 
subunit. Both types of tumors also share a transcriptional 
dysregulation of the three nAChR subunit genes grouped 
at the chromosomal locus (15q25.1) that predisposes to 
lung cancer; gene expression was reduced (CHRNA3) 
or increased (CHRNA5 and CHRNB4). Interestingly, in 
addition to CHRNA7, only a few other nAChR subunit 
genes modified their expression due to the effect of 
tobacco (CHRFAM7A, CHRNA5, CHRNA9) or to the 
Figure 2: Frequency distribution of α7 expression versus expression of each of the remaining nAChR subunits in the 
SQC-L and ADC-L tumors.  The stacked bar charts represent the frequency distribution, in SQC-L or ADC-L tumors, for several pairs 
of categorical variables (α7 versus another nAChR subunit), each with two categories (higher or lower mRNA expression in the tumor 
compared to its paired non-tumor sample). Insert shows the categories identified with different colors. The numbers inside the stacked bars 
represent the percentage of patients in each segment. Fisher’s exact test was used for analysis; statistical significance is shown at the top 
of the bar.
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degree of tumor differentiation (CHRNA5), but these 
changes only happen in SQC-L tumors. Next, we discuss 
the most relevant results of the present study.
Lung cancer is the leading global cause of cancer 
deaths, with NSCLC predominating [28]. Cells from these 
tumors express several nAChR subtypes whose activation 
by tobacco components (i.e. nicotine and its carcinogenic 
derivatives nitrosamines) regulates cell proliferation 
and apoptotic evasion [see Ref. (12, 18) and references 
therein]. Based on these observations, it has been proposed 
that a dysregulation of expression for genes encoding 
nAChR subunits and/or a dysfunction of these receptors in 
lung tumors might be involved in cancer-related processes. 
Several qPCR studies performed in NSCLC cell lines or in 
primary tumor biopsies from NSCLC or ADC-L patients 
have revealed that only a few nAChR subunit genes 
undergo dysregulation during the carcinogenic process 
[29]. As far as we know, no study in primary tumors 
from NSCLC patients has yet analyzed whether its two 
major histologic types (SQC-L and ADC-L) differ in their 
nAChR subunit gene expression pattern. Our study fills 
this gap and incorporates two substantial improvements 
in experimental design compared to previous studies in 
primary NSCLC tumors. The first is to include sufficient 
SQC-L and ADC-L patients in the same study as to be 
able to find, under the same experimental conditions, 
differences in expression of nAChR subunit genes 
between the two types of tumor. Secondly, the fact that 
we have had access to non-tumor lung specimens for all 
our patients has made it possible to detect fine changes in 
nAChR subunit gene expression between the tumor and 
its paired non-tumor sample as well as between both types 
of tumors. 
In a previous study measuring the expression of 11 
nAChR subunit genes in 66 NSCLC primary tumors (54 
ADC-L/6 SQC-L/5 LCLC, 1 adenosquamous) surgically 
resected from Chinese patients, only two of the genes 
evaluated showed significant expression changes in the 
tumor (increased CHRNB4 and decreased CHRNA4) 
compared to expression levels in non-tumor tissues [29]. 
The findings of transcriptional dysregulation of both 
genes in NSCLC tumors concur with our results showing 
a significant increase of β4 mRNA levels in tumors 
from SQC-L and ADC-L patients as well as a dramatic 
reduction of α4 mRNA levels in ADC-L tumors, the major 
histologic tumor group included in the Lam et al. study. 
However, our results differ from those of their study in 
that we were able to observe a larger number of nAChR 
subunit genes undergoing expression changes due to the 
tumorigenic process. Some of these changes are dependent 
on the histologic tumor type (increased α7 and decreased 
β2 mRNA levels in SQC-L tumors) while others were 
Figure 3: Association of smoking and tumor differentiation grade with the expression levels of nAChR subunit mRNAs 
in lung tumor biopsies from SQC-L patients. Box-plots showing the median and interquartile range of those mRNAs whose tumor 
expression was significantly affected by smoking (A) or tumor grade differentiation (B) in SQC-L patients [35 smokers (S) versus 5 
non-smokers and second-hand smokers (NS); 22 well- or moderately-differentiated (WD) versus 18 poorly-differentiated (PD) tumors]. 
The data were analyzed using Student’s t test with unequal variance assumption (Welch’s correction) (panel A) or Mann-Whitney non-
parametric test (panel B); *p < 0.05 after comparing the indicated values.
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shared by SQC-L and ADC-L tumors (increased α5 and 
β4 and decreased dupα7 and α3 mRNA levels). Moreover, 
the significant increase of α7 mRNA levels in SQC-L but 
not in ADC-L tumors found in our study when mRNA 
expression was determined in a normalized manner (with 
respect to the paired non-tumor piece), was corroborated 
by the data on absolute expression of α7 mRNA as 
determined in both histologic tumor types. On the other 
hand, changes related to α3 and α5 mRNA levels found 
in SQC-L and ADC-L tumors in our study concur with a 
previous paper describing transcriptional dysregulation for 
CHRNA3 and CHRNA5 in lung tumor biopsies paired with 
their corresponding non-tumor specimens from 21 patients 
with ADC-L [30].
The inability to detect expression changes for α7 
and β2 mRNAs in the tumors of NSCLC patients in the 
Lam study may be due to the small number of SQC-L 
patients recruited in that study (only 6 out of 66 NSCLC 
patients) compared to the 40 SQC-L patients included in 
our study. In addition, the use of the same patient›s non-
tumor lung sample as a calibrator in the qPCR could also 
have increased the sensitivity of the technique to detect 
changes in nAChR gene expression in the tumors in our 
study, unlike the Lam study, which used a pool of seven 
non-tumor samples unrelated to the patients under study. 
In fact, our finding of increased α7 mRNA level in SQC-L 
tumors, especially in smokers, but not in ADC-L tumors, 
is consistent with previous qualitative data on α7 mRNA 
expression determined by conventional PCR in tumors 
from 28 SQC-L and 19 ADC-L patients [31].
Once we identified the nAChR subunit genes whose 
expression were changed by the carcinogenic process in 
one or another histological tumor type, the next question 
was whether such dysregulation could positively or 
negatively influence tumor growth and development. It is 
interesting to note that overexpression of α7 in SQC-L and 
ADC-L cell lines as compared to normal human bronchial 
epithelial cell lines (NHBE) has been extensively 
reported [29, 32]. Also, it has been shown that nicotine 
upregulates the expression of CHRNA7 in SQC-L and 
NHBE cell lines, both at the mRNA and protein levels 
[29, 32, 33]. Moreover, nicotine induces proliferative, 
survival and angiogenic effects mediated by the activation 
of α7-nAChRs in both types of cell lines [33–35]. In 
light of all of the foregoing, our results indicate that 
α7-nAChR would play a prominent role in the oncogenic 
Figure 4: High expression level of α7 mRNA negatively influences survival of patients with SQC-L but not those with 
ADC-L. Box-plots show the median and interquartile range of α7 mRNA levels in tumor biopsies from patients with SQC-L or ADC-L 
surviving or not at 5-year after surgery. Unlike the rest of the analyzed genes, the only significant difference found was associated with 
α7 gene expression in SQC-L non-survivors (n = 16) and survivors (n = 24). In contrast, no significant changes in tumor expression were 
observed between ADC-L non-survivors (n = 12) and survivors (n = 26) for any of the nAChR subunit gene. The data were analyzed using 
the Mann-Whitney non-parametric test; **p < 0.01 after comparing the indicated values; ns = not significant.
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process of SQC-L tumors given the significant increase 
of CHRNA7 expression in this type of tumor, especially 
in smokers or in poorly differentiated tumors. Since 
α7-mRNA levels have been correlated to the smoking 
history of SQC-L patients [33] and the majority of our 
SQC-L patients (87.5%) are smokers, the increased 
α7 mRNA levels in SQC-L tumors found in our study were 
probably associated with our patients’ smoking habits.  
Interestingly, it has been recently revealed that the 
mechanism underlying nicotine-mediated up-regulation 
of α7-nAChRs in human SQC-L cell lines occurs at the 
transcription level as the result of recruitment of Sp1-
GATA4 or Sp1-GATA6 complexes on the CHRNA7 
promoter, thereby inducing transcription and increasing α7 
mRNA expression in these cells [see Ref. 32 and references 
therein]. Since α4β2-nAChR seems to be one of the major 
inhibitors of cancer development [18], the significant 
down-regulation of CHRNA4 expression in ADC-L tumors 
that we have found would result in a reduction in the 
number of nAChRs containing the α4 subunit, and this may 
favor carcinogenesis in this histological tumor type. 
Our study is the first to detect and quantify the 
expression of the hybrid gene encoding the new dupα7 
nAChR subunit in NSCLC tumors. In both tumor types 
studied here, CHRFAM7A expression was significantly 
lower than in the paired non-tumor lung specimens. If the 
dupα7 nAChR subunit expressed in these tumors plays a 
similar role to that found in Xenopus oocytes [26], it is 
possible that deficient dupα7 subunit expression facilitates 
the oncogenic process mediated by α7-nAChRs, especially 
in SQC-L where overexpression of this nAChR subtype 
appears to be determinant to cancer progression. Further 
experiments evaluating α7-nAChR-mediated tumorigenic 
processes and their interference by dupα7 in NSCLC cell 
lines are necessary to verify the above hypothesis. 
Given the association between the CHRNA3/
CHRNA5/CHRNB4 locus and the risk of lung 
cancer, attempts have been made to elucidate the 
pathophysiological role of these three genes encoding 
α3, α5 and β4 nAChR subunits. Expression of the 
above genes appears to be vital for cell viability in the 
most aggressive type of lung cancer, SCLC. Thus, 
overexpression of the clustered nAChR genes has been 
reported in a human SCLC cell line, DMS-53 [36], and 
silencing these genes is known to reduce cell viability 
[12]. Our data showing overexpression of the genes 
encoding α5 and β4 subunits in SCQ-L and ADC-L tumors 
agree with data obtained in SCLC cell lines. However, 
unlike SCLC cell lines, the CHRNA3 that encodes the 
α3 subunit is clearly downregulated in the two NSCLC 
types analyzed in our study. The opposite results for 
CHRNA3 expression in SCLC cell lines and in NSCLC 
tumors suggests the existence of different regulatory 
mechanisms for gene expression in these two categories of 
lung cancer. In fact, like us, other authors have found that 
expression of the gene encoding the α3 subunit is halved 
in lung adenocarcinoma as compared with normal lung 
tissue [30].
Down-regulation of CHRNA3 expression in the 
two tumor types in our study could be a consequence 
of epigenetic silencing of this gene, which is a frequent 
target of aberrant DNA hypermethylation [37, 38]. 
Overexpression of CHRNA3 by ectopic expression 
induces apoptotic cell death while CHRNA3 knockdown 
by short hairpin RNA (shRNA) abolishes the cell response 
to apoptosis-inducing agents in lung cancer, suggesting 
this gene is important to human cancer cell survival 
[37]. Moreover, the interaction of nicotine with nAChRs 
containing the α5 subunit promotes cell proliferation, 
angiogenesis and invasion through the activation of 
the ERK and Akt signaling pathways, upregulation of 
HIF-1 signaling and elevation of VEGF [39]. Thus, the 
downregulation of CHRNA3 expression combined with 
upregulation of CHRNA5 expression in our SQC-L and 
ADC-L tumors might result in under-representation of 
the α3-containing nAChRs and over-representation of the 
α5-containing nAChR subtypes on the cell surface, which 
could lead to a defective cell death response and again, 
favor the carcinogenic process. 
In summary, we have observed that the number of 
nAChR subunit genes that undergo expression changes in the 
two major NSCLC histological types is higher than reported 
in previous studies. This observation is probably the result 
of the use of paired non-tumor lung samples for all patients 
included in the study. The separate analysis of gene expression 
by nAChR subunits in SQC-L and ADC-L tumors, performed 
for the first time in a single study, also allows us to reliably 
establish differences and similarities of gene expression in 
the two histological tumor types. Although dysregulated 
gene expression of certain nAChR subunits (α5 increased; 
α3 and dupα7 decreased) could contribute to the oncogenic 
process in both tumor types, the two main differences are 
the under-representation of the cancer-inhibiting α4β2-
nAChR subtype in ADC-L tumors and the overexpression 
of the main cancer-promoting α7-nAChR subtype in SQC-L 
tumors. These differences could be determinant for the 
growth of one or the other tumor type. Our results showing 
higher expression levels of α7 mRNA in SQC-L tumors from 
smokers than from non-smokers, and the observation that α4 
mRNA levels in ADC-L tumors are not affected by smoking, 
appear to support the stronger association of tobacco with the 
first tumor type than the second. Finally, our data detailing 
the expression pattern of the different nAChR subunit genes 
in SQC-L and ADC-L may enhance the understanding of 
tumorigenic processes in tobacco-related tumors.
MATERIALS AND METHODS
Patients and lung samples
Lung specimens from 78 patients diagnosed with 
NSCLC (40 SQC-L and 38 ADC-L) were obtained 
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from the IdiPAZ Biobank at the Medical University 
Hospital La Paz, Madrid. Patients underwent lung 
tumor resection and systematic lymph node dissection 
between January 2007 and June 2010. The specimens 
of tumor lung biopsy from each patient, along with their 
corresponding paired non-tumor paired lung tissue, 
were respectively obtained from the center of the tumor 
and from a non-infiltrated area of the lung distant from 
the tumor, and were confirmed by histopathological 
evaluation (7th edition of the TNM Classification for 
Lung Cancer). Optimal cutting temperature (OCT)-
embedded tissue specimens were snap-frozen in liquid 
nitrogen and stored at −80ºC until RNA extraction, and 
then categorized according to clinical information by the 
Hospital Biobank. After being duly informed, all patients 
had given written permission for their samples to be 
used in research. The Institutional Ethics Committee of 
our hospital approved the study. Histological grading of 
NSCLC types was based on the revised World Health 
Organization (WHO) classification of lung tumors [27]. 
Lepidic-predominant adenocarcinomas were classified 
as well-differentiated (G1), papillary-predominant and 
acinar-predominant adenocarcinomas were classified as 
moderately-differentiated (G2), while soli-predominant 
and micropapillary-predominant adenocarcinomas 
were classified as poorly-differentiated (G3). Squamous 
cell carcinomas with extensive keratinization are well-
differentiated, while those with little to no keratinization 
were classified as poorly-differentiated. The complete 
follow-up information was recorded; the last date of 
follow-up for survivors occurred at the end of July 2015. 
The five-year survival rate was defined as the percentage 
of patients surviving five years after surgery. Disease-free 
survival was defined as the median time (months) between 
surgery and lung cancer recurrence. The interval between 
follow-up examinations was every 3 months for the first 
2 years and every 4 months for the following 3 years.
Reverse transcription of RNA and quantitative 
real-time PCR (qPCR) 
Prior to RNA extraction, the tumor or non-tumoral 
nature of all lung specimens included in the study was 
histopathologically confirmed. Techniques for RNA 
extraction from tissues or cells, as well as gene expression 
assay by qPCR from reverse-transcribed RNA using 
SYBR green-based assays (Bio-Rad, Hercules, CA) 
and the ABI Prism 7500 Sequence Detector (Applied 
Biosystems, Foster City, CA), have been described 
elsewhere [26, 40]. Briefly, total RNA was extracted from 
lung biopsy specimens (60 to 200 mg) using the Qiagen 
RNeasy Mini Kit and cDNAs were generated by reverse 
transcription of total RNA (300 ng) using Taqman Reverse 
Transcription Reagents (Life Technologies) according to 
the manufacturer’s instructions. The set of primers listed in 
Table 3 and the following cycling conditions (95ºC for 30 s, 
followed by 40 cycles at 95ºC for 5 s and 60ºC for 30 s) 
were used for PCR amplification of nAChR genes. The next 
pair of primers [5′-TGATCAAGGGAAAGATGACCA-3′, 
5′-AACCCTCTTGCAA-TCGAAAA-3′] was employed 
to amplify the human D esterase gene (ESD) which was 
selected as an endogenous control for the PCR reaction 
since it is well-established that this gene is one of the 
most appropriate to study the gene expression profile in 
non-small cell lung cancer [41, 42]. All determinations 
were performed in triplicate and paired tumor and non-
Table 3: List of primers used to amplify the nAChR subunit genes
Subunit (reference gene) Sequences (5′–3′) Amplicon size (bp)
Tm 
(ºC)
GC content 
(%) Reference
α3 (CHRNA3) CAGAGTCCAAAGGCTGCAAGAGAGAGGGACAGCACAGCAT 149
65
64
55
55 Lips et al. 2005
α4 (CHRNA4) GTGGATGAGAAGAACCAGATGATGCAGCGCAGCTTGTAGTCGTG 74
59
62
46
60 Lam et al. 2007
α5 (CHRNA5) CTTCACACGCTTCCCAAACTCTTCAACAACCTCACGGACA 187
64
64
50
50 Lips et al. 2005
α7 (CHRNA7) GCTGCAAATGTCTTGGACAGATAACAGTCTTCACCCCTGGATAT 70
59
59
45
45 Cedillo et al. 2014
dupα7 (CHRFAM7A) CAATTGCTAATCCAGCATTTGTGGCCCAGAAGAATTCACCAACACG 102
59
60
42
50 Present paper
α9 (CHRNA9) AAAGATGAACTGGTCCCATTCCTAAGGTCATTAAACAACTTCTGAGCATAT 118
60
60
43
32 Lam et al. 2007
β2 (CHRNB2) CTGGATCCTTCCCGCTACAACTGGGTCAGCCAGACATTGGT 146
60
61
57
55 Lam et al. 2007
β4 (CHRNB4) TCACAGCTCATCTCCATCAAGCTCCTGTTTCAGCCAGACATTGGT 100
62
61
48
50 Lam et al. 2007
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tumor biopsy specimens were always analyzed in the same 
analytical run to avoid between-run variations. Reaction 
conditions were validated separately for each pair of 
primers, with single peak dissociation curves produced 
in each reaction run. The relative changes in mRNA 
expression in tumor biopsies for all nAChR subunits were 
assessed by the 2−ΔΔCt method, using their corresponding 
non-tumor paired specimens as calibrator. The number of 
α7 and dupα7 mRNA copies expressed in paired tumor 
and non-tumor biopsies were determined using a six-point 
standard curve prepared with the plasmids pcDNA3.1α7 
and pcDNA3.1dupα7-myc-His (our own laboratory 
preparation) as templates and applying the following 
formula: number = (ng * number/mole)/(bp * ng/g * g/
mole of bp) (cite website: http://cels.uri.edu/gsc/cndna.
html). 
Statistical analysis 
Differences in nAChR mRNA levels between tumor 
and non-tumor paired specimens from NSCLC patients 
were assessed by the Wilcoxon test. The Mann-Whitney 
test was used to assess differences between SQC-L or 
ADC-L tumors in regard to the α7/dupα7 mRNA ratio. The 
Spearman coefficient was used to analyze the correlation 
between expression levels of α7 mRNAs and other nAChR 
subunit mRNAs in tumor biopsies from NSCLC patients. 
The relationship between two related variables (α7 mRNA 
expression vs expression of each of the remaining nAChR 
subunits) in the tumor as compared to its paired non-tumor 
sample was analyzed by Fisher’s exact test. A normal 
distribution was assumed for groups with more than 
30 patients (Central Limit Theorem) to compare expression 
for different nAChR subunit genes between groups of 
patients with different histological stages, smoking status 
and clinical outcome within 5 years after surgery. To 
perform the above comparisons in groups smaller than 
30 patients, the Kolmogorov-Smirnov test was applied 
to evaluate the normality of the data; Student’s t test 
with unequal variance assumption (Welch’s correction) 
or Mann-Whitney non-parametric test were applied for 
normal or non-normal distribution, respectively. A p value 
< 0.05 was considered statistically significant. Analysis 
was performed with the SPSS software package (version 
17.0) and Graphpad Prism 5.0.
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cell lung carcinoma; nAChR, neuronal nicotinic 
acetylcholine receptor; NNK, nicotine-derived nitrosamines 
4-(methylnitrosamino)-1-(3-pyrydyl)-1-butanone; NNN, 
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